vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Gitlab Inc. (GTLB). Click either name above to swap in a different company.

Gitlab Inc. is the larger business by last-quarter revenue ($244.4M vs $196.0M, roughly 1.2× Axsome Therapeutics, Inc.). Gitlab Inc. runs the higher net margin — -3.4% vs -14.6%, a 11.2% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 24.6%). Gitlab Inc. produced more free cash flow last quarter ($28.4M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 22.1%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

GitLab Inc. is an American company that operates and develops GitLab, an open-core DevOps software package that can develop, secure, and operate software. GitLab includes a distributed version control system based on Git, including features such as access control, bug tracking, software feature requests, task management, and wikis for every project, as well as snippets.

AXSM vs GTLB — Head-to-Head

Bigger by revenue
GTLB
GTLB
1.2× larger
GTLB
$244.4M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+40.4% gap
AXSM
65.0%
24.6%
GTLB
Higher net margin
GTLB
GTLB
11.2% more per $
GTLB
-3.4%
-14.6%
AXSM
More free cash flow
GTLB
GTLB
$47.1M more FCF
GTLB
$28.4M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
22.1%
GTLB

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
AXSM
AXSM
GTLB
GTLB
Revenue
$196.0M
$244.4M
Net Profit
$-28.6M
$-8.3M
Gross Margin
86.8%
Operating Margin
-13.8%
-5.1%
Net Margin
-14.6%
-3.4%
Revenue YoY
65.0%
24.6%
Net Profit YoY
61.9%
-128.0%
EPS (diluted)
$-0.55
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
GTLB
GTLB
Q4 25
$196.0M
$244.4M
Q3 25
$171.0M
$236.0M
Q2 25
$150.0M
$214.5M
Q1 25
$121.5M
$211.4M
Q4 24
$118.8M
$196.0M
Q3 24
$104.8M
$182.6M
Q2 24
$87.2M
$169.2M
Q1 24
$75.0M
$163.8M
Net Profit
AXSM
AXSM
GTLB
GTLB
Q4 25
$-28.6M
$-8.3M
Q3 25
$-47.2M
$-9.2M
Q2 25
$-48.0M
$-35.9M
Q1 25
$-59.4M
$5.8M
Q4 24
$-74.9M
$29.6M
Q3 24
$-64.6M
$12.9M
Q2 24
$-79.3M
$-54.6M
Q1 24
$-68.4M
$-36.5M
Gross Margin
AXSM
AXSM
GTLB
GTLB
Q4 25
86.8%
Q3 25
87.9%
Q2 25
88.3%
Q1 25
89.2%
Q4 24
88.7%
Q3 24
88.3%
Q2 24
88.9%
Q1 24
90.2%
Operating Margin
AXSM
AXSM
GTLB
GTLB
Q4 25
-13.8%
-5.1%
Q3 25
-27.0%
-7.8%
Q2 25
-24.5%
-16.1%
Q1 25
-46.9%
-9.1%
Q4 24
-61.1%
-14.7%
Q3 24
-59.8%
-22.5%
Q2 24
-89.5%
-31.7%
Q1 24
-89.7%
-21.3%
Net Margin
AXSM
AXSM
GTLB
GTLB
Q4 25
-14.6%
-3.4%
Q3 25
-27.6%
-3.9%
Q2 25
-32.0%
-16.7%
Q1 25
-48.9%
2.7%
Q4 24
-63.1%
15.1%
Q3 24
-61.7%
7.1%
Q2 24
-91.0%
-32.3%
Q1 24
-91.1%
-22.3%
EPS (diluted)
AXSM
AXSM
GTLB
GTLB
Q4 25
$-0.55
$-0.05
Q3 25
$-0.94
$-0.06
Q2 25
$-0.97
$-0.22
Q1 25
$-1.22
$0.05
Q4 24
$-1.54
$0.18
Q3 24
$-1.34
$0.08
Q2 24
$-1.67
$-0.35
Q1 24
$-1.44
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
GTLB
GTLB
Cash + ST InvestmentsLiquidity on hand
$322.9M
$224.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$88.3M
$922.7M
Total Assets
$689.8M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
GTLB
GTLB
Q4 25
$322.9M
$224.2M
Q3 25
$325.3M
$261.4M
Q2 25
$303.0M
$255.7M
Q1 25
$300.9M
$227.6M
Q4 24
$315.4M
$176.6M
Q3 24
$327.3M
$438.6M
Q2 24
$315.7M
$420.3M
Q1 24
$331.4M
$288.0M
Stockholders' Equity
AXSM
AXSM
GTLB
GTLB
Q4 25
$88.3M
$922.7M
Q3 25
$73.7M
$866.6M
Q2 25
$73.1M
$808.3M
Q1 25
$53.2M
$775.9M
Q4 24
$57.0M
$724.7M
Q3 24
$92.9M
$642.8M
Q2 24
$102.9M
$567.8M
Q1 24
$144.0M
$571.2M
Total Assets
AXSM
AXSM
GTLB
GTLB
Q4 25
$689.8M
$1.6B
Q3 25
$669.3M
$1.5B
Q2 25
$639.8M
$1.4B
Q1 25
$596.7M
$1.4B
Q4 24
$568.5M
$1.3B
Q3 24
$561.5M
$1.4B
Q2 24
$548.2M
$1.3B
Q1 24
$545.7M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
GTLB
GTLB
Operating Cash FlowLast quarter
$-18.7M
$31.4M
Free Cash FlowOCF − Capex
$-18.7M
$28.4M
FCF MarginFCF / Revenue
-9.6%
11.6%
Capex IntensityCapex / Revenue
0.0%
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$242.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
GTLB
GTLB
Q4 25
$-18.7M
$31.4M
Q3 25
$1.0M
$49.4M
Q2 25
$-32.4M
$106.3M
Q1 25
$-43.4M
$63.2M
Q4 24
$-26.2M
$-177.0M
Q3 24
$-18.6M
$11.7M
Q2 24
$-30.1M
$38.1M
Q1 24
$-53.5M
$24.9M
Free Cash Flow
AXSM
AXSM
GTLB
GTLB
Q4 25
$-18.7M
$28.4M
Q3 25
$988.0K
$46.5M
Q2 25
$-32.4M
$105.4M
Q1 25
$-43.7M
$62.1M
Q4 24
$-26.2M
$-178.1M
Q3 24
$-18.7M
$10.8M
Q2 24
$-30.2M
$37.4M
Q1 24
$-53.6M
$24.5M
FCF Margin
AXSM
AXSM
GTLB
GTLB
Q4 25
-9.6%
11.6%
Q3 25
0.6%
19.7%
Q2 25
-21.6%
49.1%
Q1 25
-36.0%
29.4%
Q4 24
-22.1%
-90.8%
Q3 24
-17.9%
5.9%
Q2 24
-34.6%
22.1%
Q1 24
-71.4%
15.0%
Capex Intensity
AXSM
AXSM
GTLB
GTLB
Q4 25
0.0%
1.2%
Q3 25
0.0%
1.2%
Q2 25
0.0%
0.4%
Q1 25
0.3%
0.5%
Q4 24
0.0%
0.5%
Q3 24
0.1%
0.5%
Q2 24
0.1%
0.4%
Q1 24
0.1%
0.2%
Cash Conversion
AXSM
AXSM
GTLB
GTLB
Q4 25
Q3 25
Q2 25
Q1 25
10.89×
Q4 24
-5.99×
Q3 24
0.90×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

GTLB
GTLB

Subscription And Circulation$146.4M60%
Subscription Software As A Service$76.9M31%
License$15.5M6%
Professional Services And Other$5.6M2%

Related Comparisons